Breast Cancer Liquid Biopsy Market by Product Type and Geography - Forecast and Analysis 2022-2026

The breast cancer liquid biopsy market share is expected to increase by USD 464.12 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 16.35%.

The breast cancer liquid biopsy market has been broadly categorized into the following demographic segmentations: 

• Product type - Reagent kits, instruments, and services
• Geography - North America, Europe, Asia, and Rest of World (ROW)

The breast cancer liquid biopsy market vendors covered in this market study include Bio Rad Laboratories Inc., Biocept Inc., Biodesix Inc., Cardiff Oncology Inc., Epic Sciences Inc., Exact Sciences Corp., F. Hoffmann La Roche Ltd., Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Isogen Life Science BV, Johnson and Johnson, Lucence Health Inc., Menarini Silicon Biosystems SpA, MiRXES Pte Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., QIAGEN NV, Sysmex Inostics Inc., and Thermo Fisher Scientific Inc. among others.

One of the key highlights of the breast cancer liquid biopsy industry research report is the post COVID-19 impact analysis on the market, which will help companies evaluate their business approaches for the forecast period.

What will the Breast Cancer Liquid Biopsy Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Breast Cancer Liquid Biopsy Market Size for the Forecast Period and Other Important Statistics

 

Breast Cancer Liquid Biopsy Market: Key Drivers, Trends, and Challenges

The growing prevalence of breast cancer cases is notably driving the breast cancer liquid biopsy market growth, although factors such as high cost of breast biopsy may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the breast cancer liquid biopsy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Breast Cancer Liquid Biopsy Market Driver

One of the key factors driving the global breast cancer liquid biopsy industry growth is the growing prevalence of breast cancer cases, particularly in the geriatric female population. The percentage of women aged 65 years and above globally was around 9% in 2021. Breast cancer is also common in younger women.

• In July 2021, the CDC reported that around 12% of new breast cancer cases were observed in women below 45 years of age in the US.
• Approximately 41,000 women and 460 men in the US die from breast cancer every year.

Thus, the patients, especially women across the globe need to be screened regularly to check for the signs and symptoms of breast cancer. Thus, the growing prevalence of breast cancer cases will further enhance the growth of the market during the forecast period.

Key Breast Cancer Liquid Biopsy Market Trend

Programs to detect breast cancer at the early stages is one of the key breast cancer liquid biopsy market trends that is expected to impact the industry positively in the forecast period. Funding and grants offered by various government and private organizations are driving the development of new innovative products for breast cancer screening. For instance, the European Commission has funded projects such as BRIDGES and B-CAST. BRIDGES is next-generation sequencing, which allows the identification of women at a high risk of breast cancer. B-CAST offers breast cancer stratification. These tools are being developed to allow the precise identification of the chances of breast cancer in people. Moreover, vendors of breast cancer liquid biopsy are also focusing on raising funds to improve the quality of the products used for breast cancer screening, which will further support the market growth.

Key Breast Cancer Liquid Biopsy Market Challenge

One of the key challenges to the global breast cancer liquid biopsy industry growth is the high cost of breast biopsy. For instance, a breast biopsy for a person covered by health insurance may have an average cost of around USD 1,500 to USD 6,000. On the other hand, the approximate cost of a breast biopsy for patients, who are not covered by insurance, may cost USD 2,500 to USD 6,500. Moreover, patients are reluctant to opt for image-guided breast biopsy procedures because of the high cost of breast biopsy using image guidance systems. In addition, in image-guided breast biopsies, incorrect guidance systems may result in false results due to malfunction and other errors. Such factors may limit the growth of the market in focus during the forecast years.

This breast cancer liquid biopsy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global breast cancer liquid biopsy market as a part of the global life science tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the breast cancer liquid biopsy market during the forecast period.

Who are the Major Breast Cancer Liquid Biopsy Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Bio Rad Laboratories Inc.
• Biocept Inc.
• Biodesix Inc.
• Cardiff Oncology Inc.
• Epic Sciences Inc.
• Exact Sciences Corp.
• F. Hoffmann La Roche Ltd.
• Fluxion Biosciences Inc.
• Guardant Health Inc.
• Illumina Inc.
• Isogen Life Science BV
• Johnson and Johnson
• Lucence Health Inc.
• Menarini Silicon Biosystems SpA
• MiRXES Pte Ltd.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• QIAGEN NV
• Sysmex Inostics Inc.
• Thermo Fisher Scientific Inc.

 

This statistical study of the breast cancer liquid biopsy market encompasses successful business strategies deployed by the key vendors. The breast cancer liquid biopsy market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

• Bio Rad Laboratories Inc. - The company offers breast cancer liquid biopsy that includes Breast Tumor Antigen which helps in protecting mucous membranes, signal transduction, and modulation of the immune system. 
• Bio Rad Laboratories Inc. - In June 2021, the company launched the Prevalence ddPCR SARSCoV2 wastewater quantification kit for COVID19 wastewater testing. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The breast cancer liquid biopsy market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Breast Cancer Liquid Biopsy Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the breast cancer liquid biopsy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Breast Cancer Liquid Biopsy Market?

For more insights on the market share of various regions Request for a FREE sample now!

52% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for breast cancer liquid biopsy in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The rapid adoption of technology in the healthcare sector, increasing healthcare expenditure, rising prevalence of breast cancer, and growing awareness among patients about mammograms to identify breast cancer incidence will facilitate the breast cancer liquid biopsy market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 in North America in 2020 led to the imposition of lockdowns to prevent the spread of infection. The increasing number of COVID-19 cases in North America in 2020 compelled people to delay elective surgical procedures to prevent the risk of contracting COVID-19, which led to a decline of the market in focus in the region. However, the situation is expected to improve, and the market is expected to gain momentum during the forecast period in the region.

What are the Revenue-generating Product Type Segments in the Breast Cancer Liquid Biopsy Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The breast cancer liquid biopsy market share growth by the reagent kits segment will be significant during the forecast period. The growth is attributed to the advent of novel breast cancer liquid biopsy reagents that execute circulating biomarker analysis and target enrichment, an increase in funding for R&D of breast cancer liquid biopsy, and an increase in breast cancer liquid biopsy reagent kits approvals. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the breast cancer liquid biopsy market size and actionable market insights on post COVID-19 impact on each segment.

 

Breast Cancer Liquid Biopsy Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 16.35%
Market growth 2022-2026	$ 464.12 million
Market structure	Fragmented
YoY growth (%)	15.75
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 52%
Key consumer countries	US, Canada, Germany, UK, and France
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Bio Rad Laboratories Inc., Biocept Inc., Biodesix Inc., Cardiff Oncology Inc., Epic Sciences Inc., Exact Sciences Corp., F. Hoffmann La Roche Ltd., Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Isogen Life Science BV, Johnson and Johnson, Lucence Health Inc., Menarini Silicon Biosystems SpA, MiRXES Pte Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., QIAGEN NV, Sysmex Inostics Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Breast Cancer Liquid Biopsy Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive breast cancer liquid biopsy market growth during the next five years
• Precise estimation of the breast cancer liquid biopsy market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the breast cancer liquid biopsy industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of breast cancer liquid biopsy market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch